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Hepatitis B surface antigen (HBsAg), originally referred as to 
“Australia antigen” was discovered approximately 40 years ago. 
Over the years, the presence of this antigen has remained the 
hallmark of hepatitis B virus (HBV) infection. HBsAg is the viral 
envelope and is composed by 3 proteins, such as S (small, S 
domains), M (medium, preS2+S) and L (large, preS1+preS2+S) 
codified by only one open reading frame. The S-HBs protein is 
the major component of the virion envelope and the subviral 
HBsAg particles, such as filaments and spheres, while virions 
and filaments contain more M-HBs, and in particular, more 
L-HBs proteins than spheres.
1,2 In infected individuals, subviral 
particles are present in at least 100-fold excess over virions.
3 The 
processing of production and secretion of HBsAg is complex, 
and the comparative proportion of each S-, M-, L-HBsAg 
component in the serum and liver varies according to the state of 
HBV replication.
4
The recent growing interest in quantitative analysis of HBsAg 
as a clinical parameter has been based on several studies that 
observed its relationship with serum and liver HBV DNA.
5-7 In 
fact, quantification of HBsAg was introduced more than 20 years 
ago, but its clinical usefulness has been questioned due to the 
lack of appropriate standardization.
8 Consequently, HBsAg has 
long been used typically as a qualitative marker for diagnosing 
an ongoing HBV infection. Recently, a quantitative, fully 
automated chemiluminescent microparticle immunoassay for the 
detection of HBsAg became available and offered more reliable 
quantitative data for HBsAg at a wide range of concentrations.
5 It 
has been suggested that serum HBsAg levels correlate well with 
intrahepatic amounts of total HBV DNA and covalently closed 
circular DNA (cccDNA), which is responsible for viral 
persistence.
6,7 Furthermore, reduction in HBsAg serum levels 
reportedly provided good predictive ability in patients treated 
with antiviral therapy. In HBeAg-negative individuals, serum 
HBsAg levels <10 IU/mL at week 48 and on-treatment decline 
>1 log IU/mL have been significantly associated with sustained 
HBsAg clearance 3 years after treatment, while a decrease of 0.5 
log IU/mL and 1 log IU/mL in HBsAg levels at weeks 12 and 24 
of therapy, respectively, have high predictive values of a 
sustained virologic response.
9,10 Although these results suggest 
the potential clinical usefulness of quantitative HBsAg as an 
on-treatment predictor, such a good correlation was only 
observed in the setting of immunomodulatory agents (pegylated 
interferon therapy).
9,10 Thus, whether or not HBsAg serum levels 
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Figure 1. Schematic changes in HBsAg, HBeAg, BCP/PC mutants, 
and HBV DNA levels during the natural course of chronic 
hepatitis B in the Korean population with genotype C.
BCP, basal core promoter; PC, precore.
response to oral nucleos(t)ide analogues remains to be 
determined in future studies.
The significance of HBsAg levels in the natural course of 
HBV infection is another key issue in need of detailed evaluation. 
In fact, HBV replication and HBsAg/HBV-DNA production go 
through a complex process, which accompanies highly dynamic 
changes during the long-lasting interaction between virus and 
host immunity. More recently, the role of quantification of serum 
HBsAg has been explored in a subset of European and Asian 
HBV-infected cohorts. The overall correlation between HBsAg 
and HBV DNA levels was noted in both study populations.
8,11 
However, when it was analyzed separately by different phases of 
chronic HBV infection or by HBV genotypes, the correlation 
was shown to become weak or negligible.
8,11 More specificially, 
a positive correlation between serum HBsAg and HBV DNA 
levels was only observed in the early phases of infection, but 
disappeared in the late phases (HBeAg-negative status). Indeed, 
the correlation was totally absent for patients with HBV 
genotype A.
8 
The direct link between HBsAg and HBV DNA levels is an 
intriguing issue. Theoretically, the levels of the virion and 
HBsAg production would be correlated, if a potent host immune 
targets concordantly both virion and HBsAg synthesis processes, 
leading to the effective control of HBV replication. However, the 
immune target of host against viral replication versus HBsAg 
pathways may not remain in continued concordance through the 
natural course of infection. As noted in relevant studies,
8,11 the 
HBsAg/HBV DNA ratios are significantly higher in the low 
replicative phase than other phases of infection, irrespective of 
study population. This may suggest that subviral particles are 
produced far in excess of virions, with altered production of 
HBsAg between its three components of L, M, and S proteins, in 
this subset of patients.
4 Thus, the relationships between HBsAg 
and HBV DNA levels should be understood in light of the 
predominant pathway of HBsAg production versus viral 
replication in the course of chronic HBV infection (Fig. 1).
It is well known that nearly all (>95%) chronic HBV carriers 
in Korea have genotype C,
12-16 which is associated with a high 
prevalence of basal core promoter mutants, even before HBeAg 
seroconversion.
14-16 In this context, it needs to be determined 
how serum HBsAg concentration functions in the natural history 
of HBV infection within the same category of genotype C 
associated with particular viral variants among the Korean 
population. Recent Korean studies involving a large number of 
antiviral-naïve patients at various disease stages of hepatitis B 
have shown varying clinical significance of HBsAg levels 
according to the disease phases.
17-19 Cross-sectional studies in 
Korea by Yoo et al.
17 and Kim et al.
18 yielded similar findings 
regarding HBsAg levels related to the natural course of HBV 
infection (Table 1). In agreement with the previous European and 
Asian cohort studies,
8,11 HBsAg levels in the two Korean studies 
were highest at 4.1-4.2 log IU/mL in the immune tolerant phase 
and lowest at 2.3-3.1 log IU/mL in the low replicative phase 
during the course of HBV infection.
17,18 The overall relationship 
between serum HBsAg and HBV DNA levels was modest 
(r=0.383-0.700). With a stratified analysis by HBeAg status, 
there was a tendency for a better correlation between HBsAg and 
HBV DNA in HBeAg-positive patients (r=0.463-0.706), as 
compared to HBeAg-negative patients (r=0.064-0.521). In both 
studies, age was consistently identified to be negatively correlated 
with serum HBsAg levels, indicating that production of HBsAg 
proteins gradually decreases with age, under effective immune 
control of HBV replication and HBsAg synthesis.
17,18 One of the 
important concerns in studies involving the natural history of 
HBV is the fact that the classification of disease stage in HBV 
carriers is not always certain, and rather, many individuals are 
indeed on the border between different stages of HBV infection. 
Given that liver biopsies are not routinely performed in all 
patients, the current categorizing system depending on a single 
time point measurement of HBeAg and HBV DNA can potentially 
result in the misdiagnosis of a disease stage, because of the 
highly fluctuating nature of serum HBV DNA levels in each 
patient. For this reason, it is highly likely that multiple serial 
measurements of virologic markers rather than reliance on only a 
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discriminate a specific stage during the natural course of 
hepatitis B. With the introduction of HBsAg quantification in 
current practice, whether or not the employment of HBsAg 
quantification may also have a beneficial role in diagnosing the 
different stages of chronic hepatitis B is another issue to be 
further confirmed. 
With respect to this issue, the study by Chan et al.,
20 involving 
117 Chinese patients with chronic hepatitis B, investigated the 
changes in HBsAg level during the natural progression of 
disease. With a longitudinal follow-up of the untreated cohort for 
99±16 months, they showed that HBsAg levels in patients at 
immune tolerant phase remain stable and persistently high at 
approximately 5 log IU/mL. Then, the levels at immune active 
stage or around the time of HBeAg seroconversion were 
comparatively lower at 3-4 log IU/mL. After achieving HBeAg 
seroconversion, the HBsAg level decreased progressively with 
time. An HBsAg reduction of >1 log IU/mL in HBeAg-negative 
patients resulted in a better viral control, with an increased 
chance of HBsAg loss during extended follow-up. In this study, 
however, no clear cut-off value of HBsAg serum level 
discriminated HBeAg-negative patients between immuno-active 
and -inactive diseases due to significant overlap of HBsAg levels 
and a highly fluctuating levels of serum HBV DNA among these 
patients. In contrast to the results, another study involving 209 
European patients with HBeAg-negative hepatitis and genotype 
D indicated that quantification of both HBsAg and HBV DNA 
levels better discriminated between the two phases in HBeAg- 
negative patients, that is, a single-point combined quantification 
for HBsAg (<1,000 IU/mL) and HBV DNA (<2,000 IU/mL) 
yielded the most accurate identification of inactive carriers with 
a 94.3% diagnostic accuracy, comparable with that of long-term 
tight monitoring.
21 A recent Korean study by Park et al.,
19 in 
which 102 HBeAg-negative patients were recruited, also 
attempted to determine the value of HBsAg quantification for 
determining outcome of HBeAg-negative hepatitis. In this study, 
the cut-off value for HBsAg that provided the best predictive 
accuracy to discriminate inactive carriers from active carriers 
was 3.25 log IU/mL for the non-cirrhosis group and 2.57 log 
IU/mL for the cirrhosis group (Table 1).
One key question for understanding the role of HBsAg 
quantification in the natural course of HBV infection is its 
relationship with circulating HBeAg/HBV DNA levels, intrahepatic 
HBV replicative intermediates, and the significance of emerging 
viral variants. The study by Thompson et al.
22 addressed these 
critical issues through a comprehensive analysis of serum and 
liver markers of HBV replication in 149 treatment-naïve 
patients. There were significant differences in HBsAg expression 
between patients with HBeAg-positive and HBeAg-negative 
chronic hepatitis B. In HBeAg-positive patients, HBsAg was 
positively correlated with serum HBV DNA and intrahepatic 
cccDNA and total HBV DNA (r=0.69-0.76). Additionally, 
HBeAg levels also correlated with serum HBV DNA levels 
(r=0.60), although the emergence of basal core promoter/precore 
variants decreased HBeAg levels independent of viral 
replication. By contrast, in HBeAg-negative patients, HBsAg 
correlated poorly with serum HBV DNA (r=0.28), with no 
correlation between HBsAg and intrahepatic HBV replicative 
intermediates. Similarly, HBsAg expression, as measured by 
quantitative immunohistochemical staining, also showed a 
positive correlation with viral replication only in HBeAg- 
positive patients, but not in HBeAg-negative patients. The 
disconnect between HBsAg production and HBV replication in 
the HBeAg-negative phase of disease implies that HBsAg might 
be produced from additional pathways other than HBV replication 
pathway from intranuclear cccDNA. HBV replication in the life 
cycle of HBV requires encapsidation of the pre-genomic RNA 
by the core particle. Under strong immune pressure associated 
with the HBeAg-negative phase, intracellular inhibitory cytokines 
more preferentially inhibit the encapsidation process, sparing the 
HBsAg synthesis pathway. On the other hand, HBsAg can also 
be produced from viral segments integrated into the host genome, 
which often carry the sequences of the S genes, although the 
integrated sequences are not able to allow for viral replication.
22 
In this context, HBsAg production in HBeAg-negative carriers is 
preserved relative to HBV replication for a quite long time, even 
after HBeAg seroconversion. Taken together, these findings 
indicate that the relationships between HBsAg, HBeAg, serum 
HBV DNA, and HBV replicative intermediates are not simple, 
but depend on the complex interplay between host and viral 
factors evolving over a long-lasting inflammatory process.
In conclusion, quantitative HBsAg assays, which are easy to 
perform with low cost, would help to assess the stage of chronic 
hepatitis B, intrahepatic viral replicative status, and response to 
antiviral therapy. Despite such potential usefulness, there is 
extremely limited evidence to support the definitive role of 
HBsAg quantification as a clinical biomarker for the management 
of chronic hepatitis B. Studies show that the production of 
HBsAg likely undergoes evolutionary changes by a complex 
interplay between virus and host, during the natural history of 
chronic HBV infection. Thus, it is mandatory to further test the 346  The Korean Journal of Hepatology Vol. 16. No. 3, September 2010
value of quantification of this antigen in clinical practice based 
on additional studies.
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